Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ).
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced its upcoming annual general meeting scheduled for June 20, 2025. Key agenda items include the approval of financial and annual reports for 2024, re-appointment of auditors, remuneration plans for directors and supervisors, and the election of new non-executive and independent non-executive directors for the board. The meeting will also address the acquisition of wealth management products and amendments to procedural rules, indicating strategic planning and governance focus.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$219.74 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and commercialization of innovative drugs and therapies. The company operates within the pharmaceutical industry, providing a range of biopharmaceutical products and services.
Average Trading Volume: 701,173
Technical Sentiment Signal: Buy
Current Market Cap: HK$75.23B
For a thorough assessment of 6990 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue